1887
  1. Home
  2. Eurosurveillance
  3. Volume 21, Issue 22, 02/Jun/2016
  4. Article
Research article Open Access
Like 0
Download

Abstract

We estimated whether previous episodes of influenza and trivalent influenza vaccination prevented laboratory-confirmed influenza in Navarre, Spain, in season 2013/14. Patients with medically-attended influenza-like illness (MA-ILI) in hospitals (n = 645) and primary healthcare (n = 525) were included. We compared 589 influenza cases and 581 negative controls. MA-ILI related to a specific virus subtype in the previous five seasons was defined as a laboratory-confirmed influenza infection with the same virus subtype or MA-ILI during weeks when more than 25% of swabs were positive for this subtype. Persons with previous MA-ILI had 30% (95% confidence interval (CI): −7 to 54) lower risk of MA-ILI, and those with previous MA-ILI related to A(H1N1)pdm09 or A(H3N2) virus, had a, respectively, 63% (95% CI: 16–84) and 65% (95% CI: 13–86) lower risk of new laboratory-confirmed influenza by the same subtype. Overall adjusted vaccine effectiveness in preventing laboratory-confirmed influenza was 31% (95% CI: 5–50): 45% (95% CI: 12–65) for A(H1N1)pdm09 and 20% (95% CI: −16 to 44) for A(H3N2). While a previous influenza episode induced high protection only against the same virus subtype, influenza vaccination provided low to moderate protection against all circulating subtypes. Influenza vaccine remains the main preventive option for high-risk populations.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2016.21.22.30243
2016-06-02
2021-12-05
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2016.21.22.30243
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/21/22/eurosurv-21-22-2.html?itemId=/content/10.2807/1560-7917.ES.2016.21.22.30243&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Fact sheet No 211. Influenza (seasonal). Geneva: WHO; April 2009. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/index.html
  2. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterization. Surveillance report. Stockholm: ECDC; December 2013. Available from: http://www.ecdc.europa.eu/en/healthtopics/seasonal_influenza/epidemiological_data/Pages/Influenza_virus_characterisation.aspx
  3. Sauerbrei A, Langenhan T, Brandstadt A, Schmidt-Ott R, Krumbholz A, Girschick H, et al. Prevalence of antibodies against influenza A and B viruses in children in Germany, 2008 to 2010. Euro Surveill. 2014;19(5):20687.  https://doi.org/10.2807/1560-7917.ES2014.19.5.20687  PMID: 24524235 
  4. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis. 2011;204(12):1879-85.  https://doi.org/10.1093/infdis/jir661  PMID: 21998477 
  5. Epstein SL, Lo CY, Misplon JA, Bennink JR. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol. 1998;160(1):322-7. PMID: 9551987 
  6. Recommended composition of influenza virus vaccines for use in the 2013–2014 northern hemisphere influenza season. Wkly Epidemiol Rec. 2013;88(10):101-14. PMID: 23544236 
  7. Adlhoch C, Broberg E, Beauté J, Snacken R, Bancroft E, Zucs P, et al. Influenza season 2013/14 has started in Europe with influenza A(H1)pdm09 virus being the most prevalent subtype. Euro Surveill. 2014;19(4):20686.  https://doi.org/10.2807/1560-7917.ES2014.19.4.20686  PMID: 24507465 
  8. Sistema de Vigilancia de la Gripe en España. Informe semanal 4/2014. [Report of the influenza surveillance system in Spain 4/2014]. Madrid: Instituto de Salud Carlos III; 30 January 2014. N° 378. Spanish. Available from: http://vgripe.isciii.es/gripe/documentos/20132014/boletines/grn042014.pdf
  9. European Centre for Disease Prevention and Control. Weekly influenza surveillance overview. 31 January 2014. Available from: http://www.ecdc.europa.eu/en/publications/Publications/influenza-surveillance-overview-31-jan-2014.pdf
  10. Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ’s Hospital. Lancet. 1979;1(8106):33-5.  https://doi.org/10.1016/S0140-6736(79)90468-9  PMID: 83475 
  11. Davies JR, Grilli EA. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect. 1989;102(2):325-33.  https://doi.org/10.1017/S0950268800030004  PMID: 2703026 
  12. Instituto de Salud Pública y Laboral de Navarra. Protocolo de vacunación antigripal 2013-2014 [Influenza vaccination protocol 2013-2014]. Boletín Informativo. 2013;74. Spanish. Available from: http://www.navarra.es/NR/rdonlyres/AECCD760-AB2A-4841-818A-FA53478FD6DC/275548/BOL74INTCampana20132014_ModificadoFeb2014.pdf
  13. Aguilar I, Reyes M, Martínez-Baz I, Guevara M, Albéniz E, Belza M, et al. Use of the vaccination register to evaluate influenza vaccine coverage in seniors in the 2010/11 influenza season, Navarre, Spain. Euro Surveill. 2012;17(17):20154. PMID: 22551499 
  14. McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL, Friedrich TC, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis. 2014;59(10):1375-85.  https://doi.org/10.1093/cid/ciu680  PMID: 25270645 
  15. Wei CJ, Yassine HM, McTamney PM, Gall JG, Whittle JR, Boyington JC, et al. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci Transl Med. 2012;4(147):147ra114.13.
  16. He XS, Holmes TH, Sanyal M, Albrecht RA, García-Sastre A, Dekker CL, et al. Distinct patterns of B-cell activation and priming by natural influenza virus infection versus inactivated influenza vaccination. J Infect Dis. 2015;211(7):1051-9.  https://doi.org/10.1093/infdis/jiu580  PMID: 25336731 
  17. Castilla J, Martínez-Baz I, Navascués A, Fernandez-Alonso M, Reina G, Guevara M, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in Navarre, Spain: 2013/14 mid-season analysis. Euro Surveill. 2014;19(6):20700.  https://doi.org/10.2807/1560-7917.ES2014.19.6.20700  PMID: 24556347 
  18. Jimnez-Jorge S, Pozo F, de Mateo S, Delgado-Sanz C, Casas I, Garcia-Cenoz M, et al. Influenza vaccine effectiveness in Spain 2013/14: subtype-specific early estimates using the cycEVA study. Euro Surveill. 2014;19(9):20727.  https://doi.org/10.2807/1560-7917.ES2014.19.9.20727  PMID: 24626206 
  19. Valenciano M, Kissling E, Reuss A, Jiménez-Jorge S, Horváth JK, Donnell JM, et al. The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2). Vaccine. 2015;33(24):2813-22.  https://doi.org/10.1016/j.vaccine.2015.04.012  PMID: 25936723 
  20. Lytras T, Kossyvakis A, Melidou A, Exindari M, Gioula G, Pogka V, et al. Influenza vaccine effectiveness against laboratory confirmed influenza in Greece during the 2013-2014 season: a test-negative study. Vaccine. 2015;33(2):367-73.  https://doi.org/10.1016/j.vaccine.2014.11.005  PMID: 25448097 
  21. Turner N, Pierse N, Bissielo A, Huang Q, Radke S, Baker M, et al. Effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2013. Euro Surveill. 2014;19(34):20884.  https://doi.org/10.2807/1560-7917.ES2014.19.34.20884  PMID: 25188614 
  22. McNeil S, Shinde V, Andrew M, Hatchette T, Leblanc J, Ambrose A, et al. Interim estimates of 2013/14 influenza clinical severity and vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalisation, Canada, February 2014. Euro Surveill. 2014;19(9):20729.  https://doi.org/10.2807/1560-7917.ES2014.19.9.20729  PMID: 24626207 
  23. Skowronski D, Chambers C, Sabaiduc S, De Serres G, Dickinson J, Winter A, et al. Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada s sentinel surveillance network, January 2014. Euro Surveill. 2014;19(5):20690.  https://doi.org/10.2807/1560-7917.ES2014.19.5.20690  PMID: 24524234 
  24. Wilde JA, McMillan JA, Serwint J, Butta J, O’Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA. 1999;281(10):908-13.  https://doi.org/10.1001/jama.281.10.908  PMID: 10078487 
  25. Burgui R, Martínez-Baz I, Guevara M, Carlos S, Castilla J. Use of medical care during pandemic (H1N1) 2009, Navarre, Spain. Emerg Infect Dis. 2011;17(8):1463-6. PMID: 21801624 
  26. Valenciano M, Kissling E, Ciancio BC, Moren A. Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine. 2010;28(46):7381-8.  https://doi.org/10.1016/j.vaccine.2010.09.010  PMID: 20851086 
Effects of previous episodes of influenza and vaccination in preventing laboratory-confirmed influenza in Navarre, Spain, 2013/14 season
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Jes%C3%BAs+Castilla&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Castilla Jesús</a>, <a href="/search?value1=Ana+Navascu%C3%A9s&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Navascués Ana</a>, <a href="/search?value1=Mirian+Fern%C3%A1ndez-Alonso&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fernández-Alonso Mirian</a>, <a href="/search?value1=Gabriel+Reina&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Reina Gabriel</a>, <a href="/search?value1=Esther+Alb%C3%A9niz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Albéniz Esther</a>, <a href="/search?value1=Francisco+Pozo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pozo Francisco</a>, <a href="/search?value1=Nerea+%C3%81lvarez&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Álvarez Nerea</a>, <a href="/search?value1=Iv%C3%A1n+Mart%C3%ADnez-Baz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Martínez-Baz Iván</a>, <a href="/search?value1=Marcela+Guevara&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Guevara Marcela</a>, <a href="/search?value1=Manuel+Garc%C3%ADa-Cenoz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">García-Cenoz Manuel</a>, <a href="/search?value1=F%C3%A1tima+Irisarri&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Irisarri Fátima</a>, <a href="/search?value1=Itziar+Casado&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Casado Itziar</a>, <a href="/search?value1=Carmen+Ezpeleta&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ezpeleta Carmen</a>, <a href="/search?value1=Primary+Health+Care+Sentinel+Network+and+Network+for+Influenza+Surveillance+in+Hospitals+of+Navarra&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Primary Health Care Sentinel Network and Network for Influenza Surveillance in Hospitals of Navarra</a></span>. Effects of previous episodes of influenza and vaccination in preventing laboratory-confirmed influenza in Navarre, Spain, 2013/14 season. <a href="/content/ecdc">Euro Surveill.</a> 2016;21(22):pii=30243. <a href="https://doi.org/10.2807/1560-7917.ES.2016.21.22.30243" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2016.21.22.30243</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 27 Jul 2015;&nbsp;&nbsp; <span class="generated">Accepted</span>: 25 Feb 2016 </span> </p>
/content/10.2807/1560-7917.ES.2016.21.22.30243
/content/10.2807/1560-7917.ES.2016.21.22.30243
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error